Gastric cancer incidence based on endoscopic Kyoto classification of gastritis.
Atrophy
Endoscopy
Gastric cancer
Gastritis
Intestinal metaplasia
Kyoto classification
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
03
06
2023
revised:
20
07
2023
accepted:
28
07
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
Gastric cancer (GC) incidence based on the endoscopic Kyoto classification of gastritis has not been systematically investigated using time-to-event analysis. To examine GC incidence in an endoscopic surveillance cohort. This study was retrospectively conducted at the Toyoshima Endoscopy Clinic. Patients who underwent two or more esophagogastroduodenoscopies were enrolled. GC incidence was based on Kyoto classification scores, such as atrophy, intestinal metaplasia (IM), enlarged folds (EFs), nodularity, diffuse redness (DR), and total Kyoto scores. Hazard ratios (HRs) adjusted for age and sex were calculated using a Cox hazard model. A total of 6718 patients were enrolled (median age 54.0 years; men 44.2%). During the follow-up period (max 5.02 years; median 2.56 years), GC developed in 34 patients. The average frequency of GCs per year was 0.19%. Kyoto atrophy scores 1 [HR with score 0 as reference: 3.66, 95% confidence interval (CI): 1.06 to 12.61], 2 (11.60, 3.82-35.27), IM score 2 (9.92, 4.37-22.54), EF score 1 (4.03, 1.63-9.96), DR scores 1 (6.22, 2.65-14.56), and 2 (10.01, 3.73-26.86) were associated with GC incidence, whereas nodularity scores were not. The total Kyoto scores of 4 (HR with total Kyoto scores 0-1 as reference: 6.23, 95%CI: 1.93 to 20.13, A high total Kyoto score (≥ 4) was associated with GC incidence. The endoscopy-based diagnosis of gastritis can stratify GC risk.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer (GC) incidence based on the endoscopic Kyoto classification of gastritis has not been systematically investigated using time-to-event analysis.
AIM
OBJECTIVE
To examine GC incidence in an endoscopic surveillance cohort.
METHODS
METHODS
This study was retrospectively conducted at the Toyoshima Endoscopy Clinic. Patients who underwent two or more esophagogastroduodenoscopies were enrolled. GC incidence was based on Kyoto classification scores, such as atrophy, intestinal metaplasia (IM), enlarged folds (EFs), nodularity, diffuse redness (DR), and total Kyoto scores. Hazard ratios (HRs) adjusted for age and sex were calculated using a Cox hazard model.
RESULTS
RESULTS
A total of 6718 patients were enrolled (median age 54.0 years; men 44.2%). During the follow-up period (max 5.02 years; median 2.56 years), GC developed in 34 patients. The average frequency of GCs per year was 0.19%. Kyoto atrophy scores 1 [HR with score 0 as reference: 3.66, 95% confidence interval (CI): 1.06 to 12.61], 2 (11.60, 3.82-35.27), IM score 2 (9.92, 4.37-22.54), EF score 1 (4.03, 1.63-9.96), DR scores 1 (6.22, 2.65-14.56), and 2 (10.01, 3.73-26.86) were associated with GC incidence, whereas nodularity scores were not. The total Kyoto scores of 4 (HR with total Kyoto scores 0-1 as reference: 6.23, 95%CI: 1.93 to 20.13,
CONCLUSION
CONCLUSIONS
A high total Kyoto score (≥ 4) was associated with GC incidence. The endoscopy-based diagnosis of gastritis can stratify GC risk.
Identifiants
pubmed: 37664152
doi: 10.3748/wjg.v29.i31.4763
pmc: PMC10473921
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4763-4773Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Gastroenterol Res Pract. 2022 Mar 9;2022:7639968
pubmed: 35309108
Scand J Gastroenterol. 2022 May;57(5):574-580
pubmed: 34994675
Gastrointest Endosc. 2016 Oct;84(4):618-24
pubmed: 26995689
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
BMC Gastroenterol. 2020 Jul 20;20(1):232
pubmed: 32689949
World J Gastroenterol. 2022 Nov 21;28(43):6078-6089
pubmed: 36483157
J Gastroenterol Hepatol. 2011 Oct;26(10):1570-5
pubmed: 21575058
Front Oncol. 2020 Dec 04;10:599218
pubmed: 33344250
N Engl J Med. 2001 Sep 13;345(11):784-9
pubmed: 11556297
World J Gastroenterol. 2020 Sep 21;26(35):5354-5361
pubmed: 32994693
World J Gastrointest Endosc. 2021 May 16;13(5):125-136
pubmed: 34046150
Gastric Cancer. 2020 Nov;23(6):1051-1063
pubmed: 32361784
Cancer Sci. 2015 Dec;106(12):1744-9
pubmed: 26432528
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
World J Gastrointest Endosc. 2021 Oct 16;13(10):518-528
pubmed: 34733412
JGH Open. 2018 Mar 25;2(3):80-86
pubmed: 30483568
Dig Endosc. 2022 Mar;34(3):508-516
pubmed: 34415621
Int J Cancer. 2012 Dec 1;131(11):2632-42
pubmed: 22383377
Gastroenterology. 2021 Oct;161(4):1325-1332.e7
pubmed: 34454714
J Gastroenterol Hepatol. 2017 Sep;32(9):1581-1586
pubmed: 28217843
Transl Cancer Res. 2020 Mar;9(3):1618-1624
pubmed: 35117509
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Gastric Cancer. 2023 Mar;26(2):298-306
pubmed: 36609936
Digestion. 2020;101(5):598-607
pubmed: 31302654
Gastrointest Endosc. 2023 Apr;97(4):684-693
pubmed: 36403805
Gastric Cancer. 2019 May;22(3):435-445
pubmed: 30206731
BMJ. 2015 Jul 27;351:h3867
pubmed: 26215280
Ann Med. 2022 Dec;54(1):1004-1013
pubmed: 35441573
Am J Gastroenterol. 2019 Jan;114(1):71-79
pubmed: 30315306
J Gastroenterol Hepatol. 2021 Jan;36(1):55-63
pubmed: 32656803
Intern Med. 2017;56(6):579-586
pubmed: 28321054
Gastric Cancer. 2018 Jul;21(4):579-587
pubmed: 29460004
J Gastroenterol. 2020 Mar;55(3):281-288
pubmed: 31667586
Dig Endosc. 2020 Jan;32(1):74-83
pubmed: 31309632
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastric Cancer. 2022 May;25(3):481-489
pubmed: 35067826
J Gastroenterol Hepatol. 2022 Feb;37(2):291-300
pubmed: 34569096